Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...36373839404142434445464748»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date, Trial primary completion date:  Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) (clinicaltrials.gov) -  Jun 5, 2019   
    P2,  N=164, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Dec 2017 --> Jul 2018
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Metastases:  A Phase II Study of Anlotinib in STS Patients (clinicaltrials.gov) -  May 22, 2019   
    P2,  N=166, Completed, 
    MiR-940 restricts the proliferation and invasion of CRC cells by targeting to MACC1's mRNA, and enhances the antitumor effect of Anlotinib on CRC tumors. Active, not recruiting --> Completed
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients (clinicaltrials.gov) -  May 22, 2019   
    P1,  N=22, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=16 --> 22 | Trial completion date: Dec 2017 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Aug 2018
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date, Metastases:  Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (clinicaltrials.gov) -  May 21, 2019   
    P2/3,  N=419, Completed, 
    Recruiting --> Completed | N=16 --> 22 | Trial completion date: Dec 2017 --> Aug 2018 | Trial primary completion date: Dec 2017 --> Aug 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2019
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Trial completion date, Trial primary completion date:  Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) (clinicaltrials.gov) -  May 21, 2019   
    P2/3,  N=113, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Metastases:  ALTN: A Phase II Study of Anlotinib in MTC Patients (clinicaltrials.gov) -  May 21, 2019   
    P2,  N=58, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Active, not recruiting --> Completed
  • ||||||||||  AL2846 / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Metastases:  A Study of AL2846 on Tolerance and Pharmacokinetics (clinicaltrials.gov) -  May 21, 2019   
    P1,  N=20, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Oct 2020 | Trial primary completion date: Dec 2018 --> Oct 2020
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date, Trial primary completion date:  Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) (clinicaltrials.gov) -  May 21, 2019   
    P2/3,  N=91, Completed, 
    Trial completion date: Dec 2018 --> Oct 2020 | Trial primary completion date: Dec 2018 --> Oct 2020 Recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Trial completion date, Trial primary completion date:  Study of Anlotinib in Patients With Primary Malignant Bone Tumors (clinicaltrials.gov) -  May 21, 2019   
    P2,  N=40, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open:  B2019-048-01: Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma (clinicaltrials.gov) -  May 20, 2019   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019 Active, not recruiting --> Recruiting
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date:  Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (clinicaltrials.gov) -  May 16, 2019   
    P2,  N=120, Completed, 
    Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2019
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    New trial, Real-world evidence, Real-world, Metastases:  Anlotinib Therapy in Patients With Advanced Lung Cancer. (clinicaltrials.gov) -  May 6, 2019   
    P,  N=1000, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date, Metastases:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=43, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date, Metastases:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Mar 13, 2019   
    P2,  N=43, Active, not recruiting, 
    Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Sep 2018 --> Mar 2018
  • ||||||||||  docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  PROACH: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (clinicaltrials.gov) -  Feb 19, 2019   
    P2,  N=188, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2022 --> Sep 2022 | Initiation date: Nov 2018 --> Mar 2019 | Trial primary completion date: Nov 2021 --> Apr 2022
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment change, Metastases:  Anlotinib and Irinotecan for Ewing Sarcoma (clinicaltrials.gov) -  Feb 15, 2019   
    P1/2,  N=47, Recruiting, 
    Trial completion date: May 2022 --> Sep 2022 | Initiation date: Nov 2018 --> Mar 2019 | Trial primary completion date: Nov 2021 --> Apr 2022 N=22 --> 47
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Phase classification, Metastases:  Anlotinib and Irinotecan for Ewing Sarcoma (clinicaltrials.gov) -  Jan 30, 2019   
    P1/2,  N=22, Recruiting, 
    N=22 --> 47 Phase classification: P2 --> P1/2